Year: 2017
Type: article
Abstract: In this thesis work, we investigate the role of autophagy in normal and malignant hematopoiesis.In normal hematopoiesis, we study the mechanism of autophagy regulation by mTOR in hematopoietic stem and progenitor cells (HSPCs) using genetic mTOR knockout and knock-in mouse models.We find that HSPCs have varied basal autophagy activity in different subpopulations, higher in more primitive hematopoietic stem cells (HSC) and lower in more differentiated progenitor cells, suggesting varied dependence on autophagy in these cells.We also observe that the autophagy activity responds differently to mTOR deletion in HSPCs subpopulations.HSC and GMP subpopulations show mTOR independent autophagy regulation, while CMP has increased autophagy activity upon mTOR deletion.We speculate that a compensatory kinase pathway in HSC and GMP exists to negatively regulate autophagy activity upon mTOR loss in HSC population based on our kinase inhibitor data.We also find that the autophagy response in mTOR knock-in cells is similar to mTOR knockout, suggesting that mTOR regulates autophagy through its kinase function, not a protein scaffolding effect.The autophagy response in Raptor knockout cells mimics that of the mTOR knockout, indicating that mTORC1 regulates autophagy in HSPCs.This project is progressing and more studies are needed to validate our current observations and conclusions.In malignant hematopoiesis, we investigate the therapeutic potential of inhibiting autophagy for AML treatment.We show that Kmt2a/Mll-Mllt3/Af9 AML (MA9-AML) cells have high autophagy flux compared to normal bone marrow cells, but autophagy-specific targeting, either through Rb1cc1-disruption to abolish autophagy initiation, or via Atg5-disruption to prevent autophagosome membrane elongation, does not affect the growth or survival of MA9-AML cells, either in vitro or in vivo.Mechanistically, neither Atg5 nor Rb1cc1 disruption impairs the endolysosome formation or survival signaling pathways.The autophagy inhibitor, chloroquine, shows autophagy-independent anti-leukemic effects in vitro but has no efficacy in vivo likely due to limited achievable drug efficacy in blood.Further, vesicular exocytosis appears to mediate chloroquine resistance in AML cells and exocytotic inhibition significantly enhances the antileukemic effect of chloroquine.Thus, the autophagy inhibitor chloroquine can induce leukemia cell death in vitro in an autophagy-independent manner but with inadequate efficacy in vivo, and vesicular exocytosis is a possible mechanism of chloroquine resistance in MA9-AML.This study also reveals that autophagy-specific targeting is unlikely to benefit MA9-AML therapy.iii iv Acknowledgement I would like to thank my advisor, Dr. Yi Zheng, who led me into the scientific world.His talent and enthusiasm for science had inspired me throughout my Ph.D. education.He is a great mentor.The freedom that he gives to his students greatly helps us forming the ability of independent thinking, which is the most important thing I learned and valued during my graduate life.He also offered timely guidance when I got puzzled in my research.He is always patient, humorous and considerate.
Author: Xiaoyi Chen
Institution: University of Cincinnati
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2747355033
